ASCO GU 2020: Response Rates and Survival Remain Superior with Nivolumab Over Everolimus >5 Years in Advanced Renal Cell Carcinoma
Nivolumab monotherapy has shown persistent efficacy and safety.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.